NK vs. ADPT, PSTX, AVXL, RLAY, SANA, IMTX, REPL, CGEM, LENZ, and AUTL
Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), Anavex Life Sciences (AVXL), Relay Therapeutics (RLAY), Sana Biotechnology (SANA), Immatics (IMTX), Replimune Group (REPL), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), and Autolus Therapeutics (AUTL). These companies are all part of the "medical" sector.
NantKwest vs.
Adaptive Biotechnologies (NASDAQ:ADPT) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
Adaptive Biotechnologies presently has a consensus target price of $6.75, indicating a potential downside of 9.40%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Adaptive Biotechnologies is more favorable than NantKwest.
Adaptive Biotechnologies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500.
99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 6.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Adaptive Biotechnologies had 4 more articles in the media than NantKwest. MarketBeat recorded 4 mentions for Adaptive Biotechnologies and 0 mentions for NantKwest. Adaptive Biotechnologies' average media sentiment score of 0.44 beat NantKwest's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.
NantKwest has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.
Adaptive Biotechnologies has a net margin of -110.13% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Adaptive Biotechnologies' return on equity.
NantKwest received 178 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. However, 57.58% of users gave Adaptive Biotechnologies an outperform vote while only 50.28% of users gave NantKwest an outperform vote.
Summary
Adaptive Biotechnologies beats NantKwest on 10 of the 18 factors compared between the two stocks.
Get NantKwest News Delivered to You Automatically
Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantKwest Competitors List
Related Companies and Tools
This page (NASDAQ:NK) was last updated on 1/22/2025 by MarketBeat.com Staff
